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Summary: introduction: Leptin is an adipokine which has a direct relationship to obesity. Our aim was to measure this 
hormone in pregnant women at three months intervals throughout their pregnancies to determine the serum value of those 
who developed preeclampsia.
Material and Methods: We followed 19 women (median age 24.8 ± 5.7 years) with pre-gestational Body Mass Index (BMI) 
less than 25 kg/m2, 21 (median age 26.1 ± 4.6 years) with BMi higher than 25 kg/m2 and 16 (median age 30.9 ± 5.8 years) 
with Gestational Diabetes Mellitus (GDM) (median age 30.9 ± 5.8 years), recruited in the 1st trimester of pregnancy. 
Serum levels of leptin were measured with radioimmunoassay (RiA) technique.
Results: In the first trimester of pregnancy leptin levels showed statistically significant differences between normal 
weight and overweight-obese women (p < 0.001), diabetic women (p < 0.05) and the subgroup of preeclamptic women 
(p < 0.001). For those women with PGBMI ≥ 40 kg/m2 and leptin ≥ 40 ng/ml in the second trimester, the Odds Ratio (OR) 
to develop preeclampsia was of 47.95% CI (4.1–527.2). Analyzing leptin values with ROC curves, the greatest area under 
the curve (AUC) was for leptin in the second trimester (0.773, CI: 0.634–0.911).
Conclusion: Women with morbid obesity (BMI ≥ 40 kg/m2) had significantly higher levels of serum leptin (p < 0.01) and 
a value of 40 ng/ml of this hormone seems to be predictive of developing preeclampsia in this group of patients.
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introduction
Many pregnant women are obese (body mass index 
(BMi) > 30 kg/m2) and the prevalence of maternal obesity 
is increasing (1). Obesity in pregnancy has been linked to 
several adverse pregnancy outcomes, including spontane-
ous abortion, preeclampsia, gestational diabetes (GDM), 
fetal macrosomia, cesarean delivery, and wound compli-
cations post-cesarean section. GDM is defined as varying 
degrees of carbohydrate intolerance with onset or first diag-
nosis during pregnancy (2).
it is recognised that the initiation of dietary or pharma-
cological therapy after 24 weeks gestation is likely too late 
to favorably impact fetal or maternal health. Consequently, 
some authors have proposed the term gestational prediabe-
tes to identify women in early pregnancy (e.g., 12 weeks 
gestation) at risk for developing GDM using conventional 
glycemic testing (3).
it is worldwide accepted that preeclampsia is a multi-
system disorder characterized by pregnancy-induced or 
gestational hypertension and new-onset proteinuria during 
the second half of pregnancy and is a foremost cause of ma- 
ternal death (4). Therefore, the early identification of pa- 
tients with an increased risk for preeclampsia is one of the 
most important goals in obstetrics.
Recently, it has been suggested that impaired regula-
tion of complex interactions among various adipokines 
plays an important role in the development of preeclamp-
sia (5). For instance, elevated leptin levels may be in- 
volved in the pathogenesis of preeclampsia and be asso-
ciated with the development of severe disease (6; 7). 
Besides, leptin gene and leptin receptor gene polymor-
phisms have also been implicated in the development of 
preeclampsia (8–10).
The aim of this study was to measure the sensibil-
ity and specificity of leptin serum levels in lean, over-
weight-obese and diabetic pregnant women throughout 
their pregnancies to determine if this hormone could 
serve as an early prognostic marker for preeclampsia 
risk.
ORiGiNAL ARTiCLES




This was a cohort study conducted in the Maternal Per-
inatal Hospital “Mónica Pretelini” (HMPMP) from January 
1, 2009, to November 30, 2010.
Accepting an alpha risk of 0.05 and a beta risk of 0.2 
in a bilateral contrast, 17 subjects per group were needed 
to detect a difference equal to or greater than 0.6. it was 
assumed a proportion of 0.035 positive cases (preeclamp-
sia) in one of the groups. The estimation of loses was of 
0.1 (11).
Preeclampsia was diagnosed and classified according to 
the criteria specified by the technical bulletin of the Amer-
ican College of Obstetricians and Gynecologists (ACOG) 
and the National High Blood Pressure Education Program 
(NHBPEP) working Group Report on High Blood Pressure 
in Pregnancy (12).
Subjects
Women were recruited at their first visit at 10–12 weeks 
gestation. They were asked to attend after an overnight fast 
and were tested between 0700 and 0900 h. Three groups of 
pregnant women were formed: a) normal weight (pre-ges-
tational (PG) BMi < 25 kg/m2), b) overweight-obese 
(PGBMI ≥ 25 kg/m2) and c) hyperglycemic in the first tri-
mester of pregnancy confirmed as GDM in women previ-
ously known to be normoglycemic.
Exclusion criteria were type 1 diabetes mellitus, chronic 
hypertension or twin pregnancy. Those women with incom-
plete medical records or less than two nutritional visits dur-
ing the pregnancy were considered lost to the study.
Measures in each trimester
Anthropometric assessment
Body weight was measured in an overnight fasting status 
without shoes in a minimal clothing state by the use of a dig-
ital scale (Seca, Hamburg, Germany) to the nearest 0.1 kg. 
Height was measured using a non-stretched tape measure 
(Seca, Hamburg, Germany) to the nearest 0.1 cm. PGBMi 
was calculated as weight in kg divided by height in meters 
squared based on the prenatal chart or self-reported weight.
Blood pressure
Blood pressure (BP) was recorded using a standard 
sphygmomanometer (Riester Big Ben® Square, Germa-
ny) and appropriately sized cuff, that was changed to an 
electronic monitor (Mercury, Mennem Medical) in case of 
preeclampsia.
Laboratory
Blood samples were collected to measure albumin (mg/dl), 
cholesterol (mg/dl), creatinine (mg/dl), glucose (mg/dl), 
triglycerides (mg/dl), uric acid (mg/dl), liver enzymes 
(Dimension Rx L Max, Dade Behring), hemoglobin (g/dl) 
(Advia 120, Bayer Health) and general urine test according 
to standardized procedures recommended by the interna-
tional Federation of Clinical Chemistry and Laboratory 
Medicine (iFCC).
Serum levels of leptin (Millipore/Linco., USA, Cat. 
HL-8IHK) and adiponectin (Millipore/Linco., USA, Cat. # 
HADP-61HK) were determined by means of a double anti-
body radioimmunoassay (RiA) using materials and proto-
cols supplied by the provider. For leptin, the sensitivity of 
the assay was 0.437 ng/ml + 2 SD (100 μl sample size), 
with an intraassay coefficient of variation (CV) of 3.4% to 
8.3% and an interassay CV of 3.6% to 6.2%. For adiponec-
tin the sensitivity was of 1 ng/ml, with an intraassay CV of 
1.78% to 3.59%, an interassay CV of 6.9% to 9.25%, and a 
recovery rate of 99% to 117% for adiponectin.
Gestational diabetes test
At the time of recruitment the medical staff used the fol-
lowing risk factors to screen women for GDM: a first-de-
gree relative with diabetes, a history of GDM or macro-
somia, persistent glucosuria, a rapid or excessive weight 
gain during early pregnancy, a random plasma glucose 
≥ 7 mmol/l. Women with one or more of these factors 
underwent the standard 100 g (Silanes Laboratory, Mexico) 
3-h oral glucose tolerance test (OGTT) after an overnight 
fast. The diagnosis of GDM was made according to the 
National Diabetes Data Group (NDDG) (13).
Diet
All women were given individualized dietary advice 
from a qualified dietitian. Compliance with the dietary reg-
imen was evaluated weekly during visits to the high-risk 
pregnancy clinic.
Statistical analysis
we used the SPSS version 16. Continuous variables 
were expressed in means ± standard deviation (SD). initial 
data were assessed through simple crosstabulations and by 
using χ2 test for categorical variables. Kruskal Wallis and 
Mann-whitney U tests were used as the variables were not 
normally distributed. Multivariable test were performed 
to evaluate the effect of covariates on leptin, systolic and 
diastolic BP. A Kaplan Meier curve was developed for 
censored cases of preeclampsia with leptin values above 
40 ng/ml.
Receiver Operating Characteristic (ROC) curves were 
used with each variable and in the cases of preeclampsia. 
A p value ≤ 0.05 was considered statistically significant.
Ethics
This study was approved by the Ethical and Research 
Committee of the HMPMP, code: 2009-07-55 and regis-
tered in Clinical Trials (ID: NCT01649167). All partici-
pants provided written informed consent.




we followed 19 women of normal weight (median age 
24.8 ± 5.7 years), 21 women who were overweight-obese 
(median age 26.1 ± 4.6 years) and 16 women with diabetes 
mellitus (median age 30.9 ± 5.8 years). The mean weight 
gain was in the ranges described by the institute of Med-
icine (IOM), 10.5 ± 1.7, 6.5 ± 3.4 and 11.4 ± 6.4 kg for 
these three groups. Table 1 shows the baseline demo-
graphic, clinical and metabolic characteristics of the study 
population in pregnancy, stratified into the three gesta-
tional groups.
measures
Measures with significant differences are synthesized 
in table 2. With the Kruskal Wallis test, we found signifi-
cant statistical differences in the following variables: age, 
pre-gestational weight, height, PGBMi, weeks’ gestation, 
systolic BP, diastolic BP, cholesterol (1st and 2nd trimes-
ter), glucose (1st and 2nd trimester), leptin (1st and 2nd 
trimester), triglycerides (1st trimester) and baby weight. 
There were no significant differences among the groups 
with respect to parity.
Tab. 1: Sociodemographic and clinical characteristics
Normal BMi > 25 GDM
Cases1 19 33.9 21 37.5 16 28.5
Age (years)2,b* 24.8  5.7 26.1 4.6 30.9 5.8
Occupation1
Home 15 79 18 85.7 14 87.5
with job 4 21 2 9.5 2 12.5
Parity2
Pregnancies 1.7 0.8 2.6 1.3 2.7 1.5
Scholarity1
Primary School 0 0 6 28.5 5 31.2
High School 13 68.4 10 47.6 8 50.0
College 6 31.6 4 19.0 1 6.2
University 0 0 0 0 2 12.5
Clinical measures2
Pregestational weight (kg)a,b*** 52.5 6.1 75.1 12.7 84.1 13.9
PGBMi
(kg/m2)a,b*** 21.7 1.5 30.6 3.7 34.9 5.4
weeks of gestationb*** 39.3 0.7 38.4 1.9 37 2.9
Baby weight (kg)b*** 3091.5 222.4 2946.4 493.8 2658.5 549
Preeclampsia1 0 0 4 19 4 25
iUGR1 0 0 3 14.2 5 31.25
1 n and percentage; 2 mean ± Standard deviation; BMi: body mass index; iUGR: intrauterine growth restriction, PGBMi: 
pregestational body mass index. a (between normal weight and overweight-obese women), b (between normal weight and 
diabetic women). * p < 0.05, ** p < 0.01, *** p < 0.001
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Comparing the results of women who were normal 
weight with women who were overweight-obese, the 
first group had lower levels of pre-gestational weight 
(p < 0.001), PGBMi (p < 0.001), diastolic BP (1st and 3rd 
trimester: p < 0.001, 2nd trimester: p < 0.01), systolic BP 
(1st and 3rd trimester: p < 0.001), glucose and triglycer-
ides in the 1st trimester (p < 0.05) and leptin (1st trimester: 
p < 0.001, 2nd trimester: p < 0.05).
Comparing women of normal weight versus women 
with diabetes, the first group was younger (p < 0.001), 
reached more weeks of gestation and babys’ weight 
(p < 0.001) and showed lower levels in pre-gestational 
weight (p < 0.001), PGBMi (p < 0.001), cholesterol (2nd 
trimester), glucose (1st and 2nd trimester: p < 0.001, 3rd 
trimester: p < 0.01), leptin (1st trimester) (p < 0.05) and 
triglycerides (1st trimester).
Between normal weight women and the subgroup 
of preeclamptic women, the second group was older 
(p < 0.001), reached less weeks’ gestation (p < 0.05), and 
had higher values in glucose (1st trimester: p < 0.001, 2nd 
trimester: p < 0.01), cholesterol (1st trimester: p < 0.001, 
2nd trimester: p < 0.01), leptin (1st trimester: p < 0.001, 
3rd trimester: p < 0.05), pre-gestational weight, PGBMi 
and triglycerides (1st trimester) (p < 0.001).
Comparing overweight-obese women with diabetic 
pregnant women, the first group was younger (p < 0.05), 
reached more weeks of gestation (p < 0.05) and babys’ 
weight (p < 0.01), had lower levels of PGBMi (p < 0.01), 






c (152.6 ± 28.2
vs 176.6 ± 23.2)*
b (219.9 ± 31.4
vs 183.8 ± 45.7)*
c (219.9 ± 31.4
vs 196.8 ± 17.7)**
Systolic blood pressure
(mm Hg)
a (101.3 ± 8.1
vs 111.3 ± 10.7)***
c (101.3 ± 8.1
vs 122.6 ± 11.7)***
c (109.7 ± 3.8
vs 128.7 ± 8.4)***
a (115.1 ± 3.1
vs 128.2 ± 11.1)***
c (115.1 ± 3.1
vs 145 ± 8.1)***
Diastolic blood pressure
(mm Hg)
a (66 ± 4.8
vs 72.9 ± 5.8)***
c (66 ± 4.8
vs 81.2 ± 7.9)*** 
a (70 ± 3.3
vs 74 ± 6.7)**
c (70 ± 3.3
vs 85.1 ± 13.9)***
a (76 ± 2.3
vs 85 ± 5.7)***
c (76 ± 2.3
vs 96 ± 3.7)***
Glucose
(mg/dl)
a (82.1 ± 6.4
vs 87.7 ± 7.2)*
b (82.1 ± 6.4
vs 113.4 ± 31)***
c (82.1 ± 6.4
vs 99.1 ± 21)***
b (79.6 ± 6.3
vs 96.4 ± 13.7)***
c (79.6 ± 6.3
vs 90.1 ± 11.4)**
b (78.1 ± 6.6
vs 93.4 ± 15.8)**
Leptin
(ng/ml)
a (29.6 ± 11
vs 45.8 ± 13.1)***
b (29.6 ± 11
vs 40.3 ± 9.6)*
c (29.6 ± 11
vs 46 ± 7)***
a (36.8 ± 13.9
vs 49.9 ± 15.1)*
c (36.8 ± 13.9
vs 54.6 ± 5.6)**
c (38.8 ± 12
vs 55.4 ± 8.8)*
Triglycerides
(mg/dl)
a (125.4 ± 27.6
vs 165.5 ± 47.9)*
b (125.4 ± 27.6
vs 170.8 ± 56.7)*
c (125.4 ± 27.6
vs 172 ± 59.6)***
a (between normal weight and overweight-obese women), b (between normal weight and diabetic women), c (between 
normal weight and preeclamptic women).
* p < 0.05, ** p < 0.01, *** p < 0.001
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diastolic and systolic BP (p < 0.001 the three evaluated 
periods) as well as glucose (1st trimester: p < 0.01, 2nd 
trimester: p < 0.05) and higher of leptin (2nd trimester) 
(p < 0.05).
Taking into account two conditionals, PGBMI ≥ 40 kg/m2 
and leptin ≥ 40 ng/ml in the second trimester, the Odds 
Ratio (OR) to develop preeclampsia was of 47.95% CI 
(4.1–527.2), p = 0.0018. Following this, the power to dis-
cern a difference was around 100% (proportion with the 
two conditionals = 80%, proportion two = 7.8%). Multi-
variate tests showed a lack of effect of age, parity, PGBMi 
and pre-gestational weight on leptin, systolic and diastolic 
BP in the second trimester.
During the follow-up period, there were no cases of 
preeclampsia in the group of pregnant women with nor-
mal PGBMi. in contrast, four patients in each of the other 
groups (overweight-obese and GDM) developed this com-
plication. Kaplan Meier curve of censored cases of preec-
lampsia with leptin values above 40 ng/ml illustrates this 
behaviour (Fig. 1).
with ROC curves, the greatest area under the curve 
(AUC) for a variable associated with preeclampsia was for 
final weight (0.826, CI: 0.714–938), followed by PGBMI 
(0.822, CI: 0.667–967) (Fig. 2). With a PGBMI value of 
38.5 kg/m2, we had a sensitivity of 0.5 and a specificity 
of 0.921. Analyzing leptin values with this test, the great-
est AUC was for leptin in the second trimester (0.773, 
CI: 0.634–0.911) followed by leptin in the first trimester 
(0.750, CI: 0.714–0.886) (Fig. 3).
After regrouping by PGBMi, those women with morbid 
obesity (PGBMI ≥ 40) had leptin value in the first trimester 
of 54 ± 9 ng/ml, while those with obesity (PGBMI ≥ 30) had 
42 ± 13.2 ng/ml and those with overweight (25 ≤ PGBMI 
< 30) had 41 ± 14.3 ng/ml.
discussion
in our population, dietary patterns during pregnancy 
were similar to those previously reported for the Mexican 
population with substantial deficiencies in intakes of cere-
als, legumes and vegetables (14).
Given the weight gain during pregnancy, this physi-
ological moment can be seen as a forced stage of over- 
Fig. 1: Kaplan Meier curve for time to preeclampsia based 
upon serum leptin levels
For leptin < 40 ng/ml: Mean Survival Time (MST): 40.63 
weeks, Standard Error (SE): 0.28, 95% Confidence Inter-
val (CI) (40.08–41.19). For leptin ≥ 40 ng/ml: MST: 39.98 
weeks, SE: 0.38, 95% CI (39.24–40.72).
Fig. 2: Receiver Operating Characteristic (ROC) curves of 
final weight and pregestational body mass index
PGBMi: pre-gestational body mass index
Fig. 3: Receiver Operating Characteristic (ROC) curves of 
serum leptin levels
Lep1: leptin in the first trimester, Lep2: leptin in the second 
trimester, Lep3: leptin in the third trimester
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weight-obesity with all of the risks of this pathology. 
Rising levels of obesity strengthen the potentially clini-
cal significance of our findings related to the increasing 
importance of first-trimester identification of women at 
the greatest risk for complications such as GDM or preec-
lampsia. in our study, higher values of systolic BP at the 
time of recruitment and at the end of gestation were corre-
lated with overweight-obese women compared to normal 
weight women.
in support of the notion of damage produced by obesity 
during gestation, was the finding that two women initially 
followed in the overweight-obese group developed GDM. 
Furthermore, of the women who developed preeclampsia, 
four were morbidly obese (PGBMI ≥ 40), three were obese 
(30 ≤ PGBMI < 40) and one was overweight (25 ≤ PGBMI 
< 30). Of the other women, there was only one who was 
morbidly obese who did not develop preeclampsia.
we also searched for possible differences in the weight 
of babies among the groups and found that this variable was 
higher in normal pregnancies than in GDM. This difference 
is attributed to the premature interruption of pregnancies in 
the last group due to preeclampsia. in fact, normal preg-
nancies had a longer duration of gestation when compared 
to the GDM group. This behavior was similar when com-
paring overweight-obese women versus the GDM group, 
with a longer duration of gestation and heavier babies in 
the former group when compared to the latter.
Similar to Ray et al. (3), we think that the actual rec-
ommendation to screen for GDM conditions is too late 
for physicians to diagnose a critical metabolic problem 
for the mother and fetus, making it obligatory to consider 
new guidelines and terms. in our work, glucose in diabetic 
women was higher than in the other groups at the moment 
of admission to our study. Fortunately, we reached meta-
bolic control after the follow-up with advice from the nutri-
tionist. Among all of the women, there was a tendency for 
cholesterol, triglycerides and leptin to increase.
Due to the worldwide diversity in the results of adi-
ponectin and pregnancy (15–18), we measured this adi-
pokine only to characterize those women with normal 
weight, and the mean values for the first, second, and third 
trimester were 14.3, 20.6 and 43 µg/ml, respectively.
Evidence shows that maternal leptin levels correlate 
with maternal weight, BMi, mid-arm circumference and 
skinfold thickness, but not with birth weight, placental 
weight or maternal height (19). Controversy exists in the 
literature, regarding maternal leptin levels in GDM. This 
discrepancy could be a result of the differences in the time 
of maternal blood sampling (20).
Some authors have published that leptin is not associat-
ed with preeclampsia and that neither adiponectin nor lep-
tin differ significantly between mild and severe cases (21; 
22). On the contrary, previous studies have demonstrated 
that plasma leptin concentrations are increased significant-
ly during the third trimester of preeclamptic pregnancies 
when compared to normal pregnancies (23). Even more, it 
has been documented that plasma leptin levels are elevated 
before preeclampsia becomes clinically evident (24). Our 
results support this late notion as leptin levels in preeclamp-
tic patients were significantly higher compared to controls 
in each trimester (46 ± 7, 54.6 ± 5.6, 55.4 ± 8.8 vs. 29.6 ± 11, 
36.8 ± 13.9, 38.8 ± 12) ng/ml. Unlike weight gain, leptin 
in pregnancy had a better AUC for cases that developed 
preeclampsia. Specifically, a leptin level of 40.2 ng/ml in 
the first trimester had a sensitivity of 0.875 and a specificity 
of 0.311 for developing preeclampsia. in addition, seven 
of eight preeclampsia cases in our cohort study had leptin 
reports above this level. The fact that the concentrations of 
leptin increased in diabetic women, despite the metabolic 
control reached, suggest that this adipokine is not modifia-
ble by insulin treatment but by BMi.
There is evidence to suggest that the placenta, rather 
than maternal adipose tissue, makes a substantial contribu-
tion to the increase of maternal leptin concentrations (25; 
26). in fact, placental leptin expression has been shown to 
be up-regulated by different pregnancy hormones such as 
chorionic gonadotrophin and 17beta-estradiol and also by 
second messengers such as cyclic adenosine 5′-monophos-
phate (27–29). Even more, the production of leptin from 
placental syncytiotrophoblasts increases with gestational 
age, leading to an increased leptin level in maternal circu-
lation (25). Although this is a very important concept, we 
were not able to collect and weight the placentas as these 
tissues were used for other studies.
In the context of our population, the key finding of 
the current study is the demonstration that elevated serum 
levels of leptin in pregnant women in the first and second 
trimesters can be predictors for preeclampsia, suggesting 
that this hormone is an important factor contributing to 
this complication of pregnancy (30). Further studies are 
required to verify whether this hypothesis is true at an ear-
ly stage of pregnancy (31). importantly, this adipokine is 
not modified by insulin treatment as with adiponectin and 
maintains a direct relationship with visceral adiposity. This 
last point, “the obesity issue” (pre-gestational BMi, weight 
gain in pregnancy) (32), could explain at least in part the 
contradictory data concerning the pattern of adipocy-
tokines’ secretion in normal and complicated pregnancies.
conclusion
Leptin values higher than 40 ng/ml in the first trimester 
was present in 87.5% of pregnant women with morbid obe-
sity who developed preeclampsia. Therefore, this adipokine 
could be useful as a prognostic marker for preeclampsia.
Some limitations for this study may be attributed to the 
relatively low number of reviewed pregnancies, which did 
not allow to run multivariable regression models to adjust 
for important covariates. Beyond the previous restriction 
mentioned, other important adipokines were not deter-
mined in this study. Probably a larger cohort may have 
yielded different results.
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